ArticleTranslational lung cancer research2025
Multimodal prehabilitation to prevent loss of cardiorespiratory fitness in patients with locally advanced lung cancer undergoing chemoimmunotherapy: protocol for a non-randomized multicentre study.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05636969 (Effects of Multimodal Prehabilitation on Cardiorespiratory Fitness and Pulmonary Function During Neoadjuvant Therapy in Patients with Locally Advanced Lung Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Multimodal Prehabilitation on Cardiorespiratory Fitness and Pulmonary Function During Neoadjuvant Therapy in Patients with Locally Advanced Lung Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) is the second most common cancer globally and a leading cause of cancer-related mortality. Although 5-year survival rates remain lower than those of other cancer types, significant improvements have been observed in recent years, largely due to the introduction of immunotherapy and targeted therapies. Recently, immune checkpoint inhibitors (ICIs) have been approved for use in combination with standard double-platinum chemotherapy in the neoadjuvant setting for resectable NSCLC, improving outcomes and extending time to recurrence. However, neoadjuvant therapy (NAT) can lead to declines in pulmonary function and cardiorespiratory fitness (CRF), thereby increasing the risk of postoperative complications. This study aims to evaluate the effects of multimodal prehabilitation on maintaining CRF and enhancing surgical resilience in patients with NSCLC undergoing neoadjuvant chemoimmunotherapy. Methods: Ambispective cohort study to evaluate the feasibility and preliminary efficacy of multimodal prehabilitation in patients with NSCLC undergoing NAT with chemoimmunotherapy. Eligible patients will be recruited from tertiary cancer centres in Spain and France. The intervention will include: (I) a supervised exercise training conducted twice weekly through the duration of NAT until surgery; (II) a nutritional assessment with a personalized dietary plan; and (III) psychological support. Additional services (such as smoking cessation counselling) will be provided if needed. The primary outcome will be changes in peak oxygen uptake (VO Discussion: This trial aims to provide data on efficacy, safety, and feasibility to support the implementation of prehabilitation for patients with resectable NSCLC undergoing NAT. Trial Registration: ClinicalTrials.gov; NCT05636969.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.